Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302
Abstract Overall survival is vital for approving new anticancer drugs but is often impractical for early‐phase studies. The tumor growth inhibition‐overall survival (TGI‐OS) model could bridge the gap between early‐ and late‐stage development. This study aimed to identify an appropriate TGI‐OS model...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.13094 |